J9177 Injection enfort vedo-ejfv 0.25mg
Also known as: enfortumab vedotin, Padcev
Intravenous injection of enfortumab vedotin-ejfv, a monoclonal antibody-drug conjugate targeting nectin-4, dosed per 0.25 milligram.
In Plain Language
bladder cancer-targeting antibody; cancer cell-killing injection
Clinical Context
Used for advanced urothelial cancer expressing nectin-4, delivering microtubule-inhibiting toxin to tumor cells.
RVU Information
CPT J9177 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J9177?
CPT J9177 (Injection enfort vedo-ejfv 0.25mg) is a J Codes (Drugs) code. Intravenous injection of enfortumab vedotin-ejfv, a monoclonal antibody-drug conjugate targeting nectin-4, dosed per 0.25 milligram.
How is J9177 administered?
CPT J9177 is administered by a healthcare provider, typically via injection or infusion. Used for advanced urothelial cancer expressing nectin-4, delivering microtubule-inhibiting toxin to tumor cells. It is used by Urology, Oncology.
When is CPT J9177 used?
Used for advanced urothelial cancer expressing nectin-4, delivering microtubule-inhibiting toxin to tumor cells.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.